Filing Details

Accession Number:
0001214659-21-009625
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-17 16:44:04
Reporting Period:
2021-09-15
Accepted Time:
2021-09-17 16:44:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737287 Allogene Therapeutics Inc. ALLO Biological Products, (No Disgnostic Substances) (2836) 823562771
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1808980 Veer Bhavnagri 210 East Grand Avenue
South San Francisco CA 94080
General Counsel No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-09-15 5,000 $2.27 426,669 No 4 M Direct
Common Stock Disposition 2021-09-15 5,000 $24.77 421,669 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-09-15 5,000 $0.00 5,000 $2.27
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
112,300 2028-06-25 No 4 M Direct
Footnotes
  1. Includes 316 shares of the Issuer's common stock acquired by the reporting person on September 15, 2021 pursuant to an employee stock purchase program.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.64 to $24.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.